Plasma (p) VEGF-A and VEGFR-2 biomarker (BM) results from the BEATRICE phase III trial of bevacizumab (BEV) in triple-negative early breast cancer (BC)

Category Primary study
JournalCANCER RESEARCH
Year 2012
This article has no abstract
Epistemonikos ID: 21e45dda36bfc050bc80345ee31819bda59a4b2e
First added on: Feb 05, 2025